ABSTRACT. Total somatomedins from milk of bovine somatotropin-treated cows were isolated and characterized to determine the relative amount of the three amino acid N-terminally truncated form of IGF-I (destripeptide IGF-I). The somatomedin fraction was isolated using organic solvent and solid-phase extractions followed by preparative reverse phase HPLC and affinity chromatography. The overall yield of IGF-I was 28%, and destripeptide IGF-I was recovered with similar efficiency. The isolated somatomedins were resolved by capillary zonal electrophoresis and identified using recombinant somatomedin standards. The concentration of destripeptide IGF-I relative to full length IGF-I was determined by amino terminal sequencing and by bioassay. Results from these experiments indicated that the level of destripeptide IGF-I in milk from somatotropin-treated cows was less than 3% of the IGF-I concentration. Destripeptide IGF
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The insulin-like growth factors (or somatomedins) are a family of polypeptides that have structural similarity to proinsulin (1) . Two principal somatomedins (IGF-I and IGF-11) have been identified in most species (2) . These two molecules share approximately 62% sequence identity (3), but the primary amino acid sequence of each of the somatomedins has been highly conserved across species. Thus, the sequence of IGF-I is identical in humans and cattle (4) and the sequence of bovine IGF-I1 is 94% identical t o the human molecule (5).
A variant of IGF-I that lacks the first three amino terminal residues (des IGF-I) was first isolated from bovine colostrum (6), where it comprises a major component (approximately 50%) of the IGF-I fraction. The des IGF-I has 5-to 10-fold greater biologic activity than IGF-I in some in vitro bioassays (5-8). The increased potency of des IGF-I appears to be due to the fact that it is not bound by several of the IGF binding proteins (8-10). Because the sequence of des IGF-I is identical to IGF-I with the exception of the truncated amino terminus, it is not possible to distinguish between these two growth factors by existing assay methods (i.e. RIA). Consequently, very little is known about the tissue distribution, concentration, or biologic significance of des IGF-I.
Both IGF-I and IGF-I1 are found in bovine milk (1 1, 12) . The concentration of IGF-I is related to parity of the animal and stage of lactation (13, 14). Administration of bST elevates the blood plasma concentrations of IGF-I (1 5). The milk concentration of IGF-I is also increased by administration of bST (16), although this increase is typically within the range of concentrations found in milk from nontreated cattle (14).
Because milk from bST-treated cows has a slightly higher concentration of IGF-I, the oral activity of this growth factor has been tested. The data indicate that IGF-I has no oral activity (1 7, 18) . Extensive data pertaining to the safety of milk from bSTtreated cows was also reviewed at a technology assessment conference convened by the National Institutes of Health. The review panel concluded that "meat and milk from bST-treated cows are as safe as those from untreated cows" (19). This same conclusion was restated in a commentary in the journal of the American Academy of Pediatrics (20) . However, it has been assumed that the increase in IGF-I in milk was due to full length IGF-I. Given that RIA cannot differentiate between IGF-I and des IGF-I, it is possible that the concentration of the truncated molecule is elevated in milk from bST-treated cows. Because des IGF-I, under some circumstances, is more bioactive than IGF-I, there has been some reservation about the safety of milk in the absence of data on the concentration of des IGF-I (2 1). We have therefore developed a procedure to isolate somatomedins from milk and methods to directly and indirectly measure the relative concentration of des IGF-I in milk from cows treated with bST.
MATERIALS AND METHODS
Isolation of somatomedins. Somatomedins were isolated from 4 L of milk pooled from six bST-treated (480 mg/2 wk) cows in mid lactation. These cows had received at least three injections of bST, and the milk was collected from d 7 of the treatment cycle. Initial extraction of IGF was similar to the method of Francis et al. (5). The milk was defatted by mixing with 0.3 volumes of 1,l ,2-trichloro-l,2,2-trifluoroethane at 5°C for 15 min in a separatory funnel. The aqueous phase was mixed with an equal volume of ethanol:12 M HC1(87.5:12.5, vo1:vol) at 5°C for 1 h using an Ultra Turrax (Virtis, Gardiner, NY) shear homogenizer equipped with a nonaerating mixer. Precipitated protein was removed by centrifugation (27 000 X g for 15 min at 5"C), and the supernatant was concentrated by vacuum rotary evaporation at 37°C to remove ethanol and most of the HCl. The pH of the concentrated solution was adjusted to 3.0 with 2 M sodium hydroxide and filtered (0.45 pm HT Tufryn membrane; Gelman, Ann Arbor, MI) to remove fine particulate material. Extracted IGF were adsorbed onto a column (16 x 5.5 cm) of Delta Pak C-18 (Waters, Milford, MA) and were eluted with a stepwise change in acetonitrile concentration (20 to 50%). The eluate was concentrated by vacuum evaporation and then applied to a reverse-phase HPLC column (30 X 2.8 cm) of Asahipak ODP-90 (Keystone Scientific, Bellefonte, PA). Adsorbed material was eluted with a 25 to 45% acetonitrile gradient developed in 10-column volumes at a flow rate of 10 mL/min. The somatomedin-containing fraction was concentrated as before, then loaded onto a second reverse-phase HPLC column (2.2 x 25 cm) of Vydac 2 18 TP (Vydac, Hesperia, CA). Adsorbed material was eluted with a 25 to 35% acetonitrile gradient developed in 10-column volumes at a flow rate of 1 mL/min. The somatomedin-containing fraction was collected and concentrated as before.
IGF-I and des IGF-I in the somatomedin-enriched fraction were further purified by antibody affinity chromatography for amino terminal protein sequencing. A diethlyaminoethyl-cibacron blue column (BioRad, Richmond, CA) was used to purify the Ig fraction from antiserum raised against bovine IGF-I. This antiserum had greater than 90% cross-reactivity with des IGF-I but less than 2% cross-reactivity with IGF-11. The Ig fraction was covalently coupled to a carbonyliimidazole-activated trisacryl resin (HW-65F) according to the manufacturer's instructions (Pierce, Rockford, IL). The solid phase immunoadsorption was carried out by adding to the sample an equal weight of affinity resin suspended in 0.1 M sodium borate buffer, pH 8.5. This was then agitated on a roller mixer for 12 h at room temperature. The resin was sedimented by centrifugation (10 000 x g for 10 s) and the supernatant was added to a fresh batch of resin exactly as before. The affinity resin from the second adsorption was combined with that from the first. Adsorbed solutes were eluted batchwise by the addition of one resin volume 6 M guanidine hydrochloride and mixing for 1 h at room temperature. Resin was sedimented by centrifugation, as before, and then washed twice more with 6 M guanidine hydrochloride. The three supernatants from this step were combined and dialyzed (1 000 molecular weight cut-off membrane) at 5°C for 24 h against three changes of water. Trace protein contaminants were removed by analytical reverse-phase HPLC (0.46 x 25 cm Vydac 21 8 TP54 column) using an elution gradient from 25 to 45% acetonitrile (1 %/mL per min).
Sornatomedin RIA. RIA for IGF-I and IGF-I1 were used to determine which fractions contained somatomedins during the purification steps. These assays were carried out essentially as described by Vicini et al. (22) . Intra-and interassay coefficients of variation were 11.0 and 9.0% for the IGF-I assay and 9.1 and 15.1 % for assay of IGF-11. Cross-reactivity of recombinant des IGF-I and recombinant N-methionyl des IGF-I with the antiserum used in the IGF-I RIA was greater than 90% for both variants. The acidified-ethanol extraction step was omitted for samples generated after acid-ethanol extraction of the milk because IGF binding proteins were undetectable by ligand blotting [method of Hossenlopp et al. (23) l. Organic solvent was removed from samples by vacuum desiccation at room temperature, and samples were reconstituted with RIA buffer.
Recovery of IGF-I and des IGF-I. Recombinant IGF-I (Monsanto lot D-17) and recombinant des IGF-I (N-methionyl des IGF-1:des IGF-I, 4: 1; Monsanto lot JG-3) were radiolabeled with Iz5I using a lactoperoxidase procedure. The radioiodinated growth factors were individually added to a small volume of acid-ethanol extracted milk. These samples were run on small scale versions of the reverse-phase columns used to purify the somatomedins. We were therefore able to determine if the recovery of IGF-I and des IGF-I was Cquivalent for each of the reversephase purification steps.
Capillary zonal electrophoresis. A Beckman Pace 2000 capillary zonal electrophoresis system (Beckman, Fullerton, CA) was used to resolve IGF-I, IGF-11, and des IGF-I and to determine the relative concentrations of these molecules. An open tubular uncoated fused-silica capillary column, 50 cm x 75 pm, was used with 0.2 M sodium borate buffer, pH 11. The electrophoresis was usually carried out at 15 kV and 175 pA for 30 min at 25°C.
Amino terminal protein sequencing. Gas phase automated Edman degradation chemistry was used to determine amino terminal protein sequences through at least five amino acid residues and to determine the relative amount of each sequence. The sample was augmented with an internal standard of recombinant des IGF-I. The amino terminal residue of 80% of the standard was methionine. The remaining 20% of the standard had the same amino terminal sequence as native des IGF-I. An internal standard was included to check recovery of derivitized residues. Sample was applied to a Polybrene derivatized filter disk in several aliquots followed by drying and then sequencing. An Applied Biosystems, Inc. model 470A gas phase sequencer (Foster City, CA) was used for the degradations (24) . The resulting phenylthiohydantoin amino acid derivatives were identified by reverse-phase HPLC in an on-line fashion using an Applied Biosystems, Inc. model 120A PTH analyzer fitted with a Brownlee (Foster City, CA) 2.1 mm inner diameter PTH-C18 column.
L6 myoblast proliferation assay. Proliferative activity of the somatomedin-enriched fraction was compared with activities of known amounts of standard recombinant IGF using the L6 myoblast bioassay. Proliferation of L6 myoblast cells is stimulated by des IGF-I, IGF-I, and IGF-I1 (25) . This assay was conducted essentially according to the method of Kotts et al. (26) . Briefly, the cells were plated at a density of lo3 cells/cm2 on 24-well culture plates (Costar, Cambridge, MA) in Dulbecco's minimal essential medium plus 2% FCS. Twenty-four h after plating, the medium was removed and replaced with 1 mL Dulbecco's minimal essential medium plus 2% FCS containing IGF standards or the somatomedin-enriched fraction. Care was taken to remove organic solvents from samples before they were assayed. After 24 h, the culture medium was replaced with fresh test medium and the cellswere incubated for an additional 48 h. Cell number was estimated at the end of this period with a fluorometric assay for DNA (27) . Each sample was assayed in triplicate wells and intraassay coefficient of variation was 4.1 to 9.8%. Samples were assayed on three separate occasions and 
RESULTS
Somatomedin purijication. The overall recovery of IGF-I in the somatomedin-enriched fraction was 28% by RIA (Table 1) with a 5 X lo5-fold enrichment by volume. The recoveries of both IGF-I and des IGF-I were determined individually using radioiodinated material and scaled down versions of the reverse phase columns used in the purification process. Given that des IGF-I is inseparable from IGF-I by most chromatographic methods, it was assumed that both molecules would be purified with equal efficiency. Results from the recovery experiments (presented in Table 2 ) indicated that this was a valid assumption.
Capillary zonal electrophoresis. It was discovered that des IGF-I could be separated from IGF-I and -11 by capillary zonal electrophoresis. Recombinant standards of des IGF-I, IGF-I, and IGF-I1 were clearly resolved by this method (Fig. 1) . Capillary zonal electrophoresis was therefore used to estimate the relative concentrations of IGF-I and des IGF-I in the somatomedinenriched fraction (Fig. 2, top panels) . Peaks corresponding to IGF-I and IGF-I1 were identified by addition of recombinant IGF-I (panel A) and IGF-I1 (panel B) to the sample. There was also a small riding peak on the leading edge of the IGF-I1 peak that could have corresponded to des IGF-I. Recombinant des IGF-I standard added to the enriched fraction eluted in the vicinity of this peak (panel C). However, retention time of the peak from added des IGF-I was not identical to that of the shoulder on the IGF-I1 peak. We were thus unable to provide clear evidence that this small peak in the somatomedin-enriched fraction was due to des IGF-I.
Amino terminal protein sequencing. We were unable to obtain ulated by all three of the somatomedins in a hose-responsive Asahi Pak 95 98 manner (Fig. 3) . Des IGF-I was 3-to 5-fold more potent than Vydac C 18 99 122 IGF-I and IGF-I was about 4-to 6-fold more potent than IGF-11. Des IGF-I is therefore a vem potent mitoaen in this bioassav.
I Fig. 1 . Capillary zonal electrophoresis of recombinant somatomedin standards. Approximately 1 nmol(8 ng) of IGF-I and des IGF-I and 0.33 nmol (2.5 ng) of IGF-I1 were injected. Peak I is des IGF-I, peak 2 is IGF-11, and peak 3 is IGF-I. definitive evidence that des IGF-I was present in the somatomedin-enriched fraction by capillary zonal electrophoresis; therefore, a more direct means of identification and quantification was required. Amino terminal sequence analysis can be used to confirm identity and provide information on the relative concentrations of a mixture of two or three proteins. However, to obtain clear results with this method, the sample being sequenced should contain only the proteins of interest. Therefore, immunoaffinity chromatography was used to remove IGF-I1 and other unidentified protein contaminants in the somatomedin-enriched fraction. Recombinant des IGF-I (30 pmol; 230 ng) was added to the immunopurified IGF-I as an internal standard to check sequencing efficiency. The recombinant material was a 4: 1 mixture N-methionyl des IGF-1:des IGF-I; thus, 80% of the standard could be differentiated from any native des IGF-I in the immunopurified sample. Results from amino terminal protein sequencing are shown in Table 3 . All of the relative molar yield of methionyl des IGF-I was from the internal standard. Assuming equal recovery of native des IGF-I and N-methionyl des IGF-I, then 6 pmol of des IGF-I was from the recombinant internal standard and 6 pmol originated from the enriched somatomedin fraction. If it is presumed that the ratio of full length IGF-I to des IGF-I in the immunopurified fraction is similar to that found in whole milk, then approximately 3% of the total IGF-I measProliferation stimulated by the somatomedFn-enriched fraction was compared with the proliferation stimulated by a mixture of IGF-I and -11 at the same concentration as present in the enriched fraction. Concentrations of IGF-I and IGF-I1 in the somatomedin-enriched fraction were determined by specific RIA. If a large proportion of the IGF-I measured by RIA was in fact des IGF-I, then the proliferation stimulated by the enriched fraction would be greater than that obtained with equivalent concentrations of IGF-I and IGF-11.
The somatomedin-enriched fraction stimulated a 149% increase in DNA. A mixture of recombinant IGF-I and IGF-I1 at equivalent concentrations as in the somatomedin fraction increased DNA by 152% in the same assay (Table 4) .
DISCUSSION
A number of growth factors have been found in mammary secretions from the several species examined to date. The type of growth factors and the concentrations vary considerably depending on the species as well as stage of lactation. Epidermal growth factor is one of the major mitogenic factors found in human milk (28) , but it is absent or undetectable in milk from cows and goats (29) . Another class of growth factors found in human milk are the somatomedins; the concentration of IGF-I is in the range 0.77 to 1.03 nM (6 to 8 ng/mL) (30) . Somatomedins are also found in ruminant milk (1 1, 12) . In dairy cattle, the concentration of IGF-I in milk from commercial dairies averaged 0.55 nM (4.3 ng/mL) (14). Des IGF-I has been purified from bovine colostrum (9, but it was unknown whether this IGF-I variant was also found in milk or if the concentration was altered by treatment with somatotropin. Because there is no specific assay for des IGF-I, it was necessary to purify the somatomedins in milk so that they could be resolved by chromatography or by amino terminal sequence analysis.
Key to the measurement of des IGF-I in milk was the development of a purification procedure that could be used to isolate both IGF-I and des IGF-I with equal efficiency as well as with high overall recovery. The four-step procedure that was developed achieved these objectives, and sufficient material was isolated from 4 L of milk to estimate the relative concentration of des IGF-I. Des IGF-I and IGF-I display very similar chromatographic behavior; thus, it was difficult to fully resolve these two growth factors, even with analytical reverse-phase HPLC. However, baseline resolution of des IGF-I from IGF-I from IGF-I1 was achieved using capillary zonal electrophoresis. Furthermore, Fig. 3 . Dose-response curves for des IGF-I (0), IGF-I (O), and IGF-I1 (W) in the L6 myoblast proliferation assay. Points are the means from three separate assays and error bars indicate SD.
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